Why the study?
Does oral activated charcoal effectively manage high serum digoxin concentrations in patients with digoxin toxicity?
Does oral activated charcoal effectively manage high serum digoxin concentrations in patients with digoxin toxicity?
Oral activated charcoal may be a safe, effective, and cost-saving alternative to digoxin-specific antibody fragments for managing selected patients with digoxin toxicity.
Answers are grounded in this paper and cite their sources.
May support charcoal in select digoxin toxicity cases; leaves open need for randomized trials before practice change.
Digoxin is one of the most commonly prescribed drugs. It is used in the management of patients with heart failure, atrial fibrillation, atrial flutter, and paroxysmal atrial tachycardia. Toxic effects of digoxin can be serious and frequent. Because of the effectiveness, ease of administration, availability of oral formulation, safety, and cost-effectiveness, activated charcoal should be considered in decreasing high serum digoxin concentrations. Patients that are admitted for monitoring due to high digoxin concentrations may be able to leave the cardiac monitored units earlier. This method of management may be able to provide significant cost savings by allowing the transfer of patients to units that require less intensive care monitoring.Due to several disadvantages of digoxin-specific antibody fragments, its use should be reserved for very specific patients. We are reporting six cases of digoxin toxicity due to either chronic oral or acute intravenous administration. Our finding supports the present literature that describes successful management of digoxin toxic patients with activated charcoal.
No takes yet. Share an insight, caveat, or question.
Tafreshi et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: